In the second world war, the physician Henry Beecher observed that some of his soldier patients, despite being injured on the ...

Now a third option is available after the U.S. Food and Drug Administration last week approved Vertex Pharmaceuticals’ ...

The Food and Drug Administration (FDA) has approved Journavx™ (suzetrigine) for the treatment of moderate to severe acute pain in adults.

Introducing Journavx: the FDA-approved non-opioid, non-addictive drug for acute pain. A major breakthrough in pain medication ...

The FDA has approved Journavx, an oral medication for treating pain that doesn't target the brain like addictive opioids.

The nonaddictive painkiller suzetrigine (Journavx) is as effective for acute pain as a common opioid treatment ...

The new drug will carry a list price of $15.50 per pill, making it many times more expensive than comparable opioids.

The greenlight for Journavx (suzetrigine), which comes on the heels of a $7.4 billion opioid settlement, could spark momentum ...

Vertex Pharmaceuticals claimed in a press release that the medication can be used for many types of moderate-to-severe acute ...

The U.S. Food and Drug Administration (FDA) approved Journavx (suzetrigine) oral tablets on Thursday as a first-in-class ...

Tris Pharma has reported positive topline outcomes from its ALLEVIATE-1 Phase III trial of cebranopadol for treating moderate-to-severe acute pain in ... was the reduction in pain intensity, measured ...

In addition to breathlessness, these patients often complained of fullness, discomfort or pain in the chest ... in a Case of Acute Mountain Sickness. Large-scale controlled trials in men airlifted ...